Finalization of acquisition reinforces Accord BioPharma and Intas’ commitment to growth in the U.S. biosimilar market
RALEIGH, NC, USA I April 14, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced today that Intas Pharmaceuticals has completed its acquisition of the UDENYCA® (pegfilgrastim-cbqv) business from Coherus BioSciences, Inc. UDENYCA, a biosimilar to Neulasta® (pegfilgrastim), expands the company’s portfolio of FDA-approved products and accelerates Accord BioPharma’s growth in the biosimilar industry.
By acquiring UDENYCA, Accord BioPharma will continue to make this treatment available to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. UDENYCA’s three administration options — autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS) — offer flexibility for patients to receive their treatment at home, on-the-go, or in the office. Since the brand’s commercial launch, more than 300,000 patients are estimated to have been treated with UDENYCA and over 1.4 million units have been sold.
The acquisition not only expands Accord BioPharma’s product offerings, but also brings a wealth of talent from Coherus BioSciences. Key Coherus employees across multiple functions, including Sales, Marketing, Finance, Supply Chain, and Quality and Manufacturing, will join Accord BioPharma, playing a crucial role in supply and services continuity/transition and expanding the company’s work around UDENYCA.
“The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavor to innovate and expand in the biosimilar space,” said Chrys Kokino, U.S. President of Accord. “We are delighted to welcome talented employees from Coherus, whose historical knowledge and expertise will complement that of our existing team, making us stronger and better equipped to achieve our goals with UDENYCA.”
“We are energized by this addition to Accord BioPharma’s portfolio because it exemplifies our commitment to improving patient access to high-quality treatments that effectively meet the needs of both patients and healthcare providers,” said Binish Chudgar, Executive Chairman and Managing Director of Intas Pharmaceuticals. “We are pleased with the successful completion of this agreement and are excited about the future opportunities it brings for Accord BioPharma in the U.S. market.”
INDICATION
UDENYCA® (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to:
- Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).
About Intas Pharmaceuticals
Intas Pharmaceuticals is a pioneer in biosimilars, having developed and launched one of the highest numbers of indigenous biosimilars in India. Intas Pharmaceuticals has a rich history of making quality biosimilars accessible to the masses in India. Intas’ products like Neukine (filgrastim), Pegasta (Pegfilgrastim), Mabtas (rituximab), Razumab (ranibizumab) and Bevatas (bevacizumab) have transformed the management of their respective therapies in India. Eleftha is the latest testament to Intas’ Biosimilar for Billions philosophy, fulfilling its commitment to provide quality care to the masses in India. Intas’ biosimilars are manufactured at Intas Pharmaceuticals’ European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit www.intaspharma.com.
About Accord BioPharma
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patients’ perspective and develop high-quality therapies that impact patients’ lives. Accord BioPharma believes in the ability of biosimilars to increase access to a number of biologic medicines, that in the past may not have been considered for patients due to their high costs. Accord BioPharma looks forward to providing one of the deepest biosimilar portfolios in the industry. For more information, visit AccordBioPharma.com.
About Coherus BioSciences
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that is expected to be synergistic with its proven commercial capabilities in oncology.
References:
- UDENYCA Prescribing Information. Coherus BioSciences; December 2023.
SOURCE: Accord BioPharma
Post Views: 1,298
Finalization of acquisition reinforces Accord BioPharma and Intas’ commitment to growth in the U.S. biosimilar market
RALEIGH, NC, USA I April 14, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced today that Intas Pharmaceuticals has completed its acquisition of the UDENYCA® (pegfilgrastim-cbqv) business from Coherus BioSciences, Inc. UDENYCA, a biosimilar to Neulasta® (pegfilgrastim), expands the company’s portfolio of FDA-approved products and accelerates Accord BioPharma’s growth in the biosimilar industry.
By acquiring UDENYCA, Accord BioPharma will continue to make this treatment available to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. UDENYCA’s three administration options — autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS) — offer flexibility for patients to receive their treatment at home, on-the-go, or in the office. Since the brand’s commercial launch, more than 300,000 patients are estimated to have been treated with UDENYCA and over 1.4 million units have been sold.
The acquisition not only expands Accord BioPharma’s product offerings, but also brings a wealth of talent from Coherus BioSciences. Key Coherus employees across multiple functions, including Sales, Marketing, Finance, Supply Chain, and Quality and Manufacturing, will join Accord BioPharma, playing a crucial role in supply and services continuity/transition and expanding the company’s work around UDENYCA.
“The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavor to innovate and expand in the biosimilar space,” said Chrys Kokino, U.S. President of Accord. “We are delighted to welcome talented employees from Coherus, whose historical knowledge and expertise will complement that of our existing team, making us stronger and better equipped to achieve our goals with UDENYCA.”
“We are energized by this addition to Accord BioPharma’s portfolio because it exemplifies our commitment to improving patient access to high-quality treatments that effectively meet the needs of both patients and healthcare providers,” said Binish Chudgar, Executive Chairman and Managing Director of Intas Pharmaceuticals. “We are pleased with the successful completion of this agreement and are excited about the future opportunities it brings for Accord BioPharma in the U.S. market.”
INDICATION
UDENYCA® (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to:
- Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).
About Intas Pharmaceuticals
Intas Pharmaceuticals is a pioneer in biosimilars, having developed and launched one of the highest numbers of indigenous biosimilars in India. Intas Pharmaceuticals has a rich history of making quality biosimilars accessible to the masses in India. Intas’ products like Neukine (filgrastim), Pegasta (Pegfilgrastim), Mabtas (rituximab), Razumab (ranibizumab) and Bevatas (bevacizumab) have transformed the management of their respective therapies in India. Eleftha is the latest testament to Intas’ Biosimilar for Billions philosophy, fulfilling its commitment to provide quality care to the masses in India. Intas’ biosimilars are manufactured at Intas Pharmaceuticals’ European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit www.intaspharma.com.
About Accord BioPharma
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patients’ perspective and develop high-quality therapies that impact patients’ lives. Accord BioPharma believes in the ability of biosimilars to increase access to a number of biologic medicines, that in the past may not have been considered for patients due to their high costs. Accord BioPharma looks forward to providing one of the deepest biosimilar portfolios in the industry. For more information, visit AccordBioPharma.com.
About Coherus BioSciences
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that is expected to be synergistic with its proven commercial capabilities in oncology.
References:
- UDENYCA Prescribing Information. Coherus BioSciences; December 2023.
SOURCE: Accord BioPharma
Post Views: 1,298
